Adherence to oral antihyperglycemic agents among older adults with mental disorders and its effect on health care costs, Quebec, Canada, 2005-2008

Preventing Chronic Disease

Volumn 12, Issue 12, 2015, Pages

  Gentil, Lia ^a   Vasiliadis, Helen Maria ^b   Préville, Michel ^b   Berbiche, Djamal ^b  

^a Charles LeMoyne Hospital Research Center ^*  (Canada)

^b HÔPITAL CHARLES LEMOYNE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

AGED; ANXIETY; COMPLICATION; DEPRESSION; DIABETES MELLITUS, TYPE 2; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HOSPITALIZATION; HUMAN; MALE; MEDICATION COMPLIANCE; QUEBEC; STATISTICS AND NUMERICAL DATA;

AGED; ANXIETY; DEPRESSION; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HEALTH SURVEYS; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; QUEBEC;

EID: 84957824533     PISSN: 15451151     EISSN: 21665435     Source Type: Journal    
DOI: 10.5888/pcd12.150412     Document Type: Article

References (29)

1. International Diabetes Federation. Diabetes atlas, 4th edition. 2013. http://www.idf.org/diabetesatlas. Accessed November 23, 2015.
2. Report from the National Diabetes Surveillance System: diabetes in Canada, 2009. Ottawa (ON): Public Health Agency of Canada. http://www.phac-aspc.gc.ca/publicat/2009/ndssdicsnsddac-09/pdf/report-2009-eng.pdf. Accessed November 23, 2015.
3. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25(11):2958-71.
4. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001;24(1):51-5.
5. IMS Institute for Health Care Informatics. Avoidable costs in U.S. health care: the $200 billion opportunity from using medicines more responsibly. https://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Institute/RUOM-2013/IHII_Responsible_Use_Medicines_2013.pdf. Accessed November 23, 2015.
6. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 2004;21(12):793-811.
7. Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002;27(3):213-20.
8. Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm 2006;12(2):130-42.
9. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and health care cost. Med Care 2005;43(6):521-30.
10. Breitscheidel L, Stamenitis S, Dippel FW, Schöffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ 2010;13(1):8-15.
11. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006;23(11):1165-73.
12. Almawi W, Tamim H, Al-Sayed N, Arekat MR, Al-Khateeb GM, Baqer A, et al. Association of comorbid depression, anxiety, and stress disorders with Type 2 diabetes in Bahrain, a country with a very high prevalence of Type 2 diabetes. J Endocrinol Invest 2008;31(11):1020-4.
13. Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002;25(3):464-70.
14. Kafonek S, Ettinger WH, Roca R, Kittner S, Taylor N, German PS. Instruments for screening for depression and dementia in a long-term care facility. J Am Geriatr Soc 1989;37(1):29-34.
15. Crum RM, Anthony JC, Bassett SS, Folstein MF. Populationbased norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269(18):2386-91.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98.
17. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50(1):105-16.
18. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25(9):2303-10.
19. Wittchen HU, Robins LN, Cottler LB, Sartorius N, Burke JD, Regier D. Cross-cultural feasibility, reliability and sources of variance of the composite international diagnostic interview (CIDI). The Multicentre WHO/ADAMHA Field Trials. Br J Psychiatry 1991;159(5):645-53, 658.
20. Erdman HP, Klein MH, Greist JH, Skare SS, Husted JJ, Robins LN, et al. A comparison of two computer-administered versions of the NIMH Diagnostic Interview Schedule. J Psychiatr Res 1992;26(1):85-95.
21. Diagnostic and Statistical Manual of Mental Disorders. (4th edition). Washington (DC): American Psychiatric Association; 1994.
22. Bucholz KK, Marion SL, Shayka JJ, Marcus SC, Robins LN. A short computer interview for obtaining psychiatric diagnoses. Psychiatr Serv 1996;47(3):293-7.
23. Préville M, Boyer R, Grenier S, Dubé M, Voyer P, Punti R, et al.;Scientific Committee of the ESA Study. The epidemiology of psychiatric disorders in Quebec's older adult population. Can J Psychiatry 2008;53(12):822-32.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5):373-83.
25. Drummond MF. Methods for the economic evaluation of health care programmes, 3rd edition. Toronto (ON): Oxford University Press; 2005.
26. Vasiliadis HM, Dionne PA, Préville M, Gentil L, Berbiche D, Latimer E. The excess health care costs associated with depression and anxiety in elderly living in the community. Am J Geriatr Psychiatry 2013;21(6):536-48.
27. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10(2 Pt 2):144-51.
28. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37(9):846-57.
29. Horn OK, Jacobs-Whyte H, Ing A, Bruegl A, Paradis G, Macaulay AC. Incidence and prevalence of type 2 diabetes in the First Nation community of Kahnawá:ke, Quebec, Canada, 1986-2003. Can J Public Health 2007;98(6):438-43.